



SYNTHESIS OF SOME NOVEL QUINAZOLINONE DERIVATIVES

P. MUTHUMANI^{*}, R. MEERA, NANDHAKUMAR, P. DEVI^a and B. KAMESWARI^b

Department of Pharmaceutical Chemistry, K. M. College of Pharmacy, Uthangudi,
MADURAI – 625 107 (T.N.) INDIA

^aDeptt. of Pharmacognosy, K. M. College of Pharmacy, Uthangudi, MADURAI – 625 107 (T.N.) INDIA

^bDeptt. of Biochemistry, K. M. College of Pharmacy, Uthangudi, MADURAI – 625 107 (T.N.) INDIA

ABSTRACT

In this work, an efficient two step synthesis for the preparation of some novel quinoxalinones has been reported. In step I, various 2-substituted-3, 1-benzoxazin-4-ones are formed by the reaction of anthranilic acid and acetic anhydride / benzoyl chloride / propionic anhydride. In step II, 2-substituted-3, 1-benzoxazin-4-ones, which are formed in step I, are condensed with valdecoxib. The resulting quinazolinone derivatives were characterized by IR, NMR, ¹³C NMR and mass spectral analysis.

Key words: 2-Substituted-3, 1-Benzoxazin-4-one, Valdecoxib, Quinazolinone derivatives, IR, NMR, Mass spectroscopy.

INTRODUCTION

Quinazolinone derivatives have been reported as antimalarial¹, diuretic², sedative and hypotension³, monoaminoxidaseinhibitoractivity⁴⁻⁶, antihypertensive⁷, antitubercular⁸, analgesic⁹, antiinflammatory¹⁰, antifibrillatory¹¹, antihistamine¹², CNSdepressant^{13,14}, anticonvulsant^{15,16}, antiparkinsonism^{17,18}, antibacterial^{19,20}, antiviral²¹, antiallergy²², anthelmintic²³, anticancer²⁴, antiHIV²⁵, antitubercular²⁶, CVS²⁷ and bronchodilator²⁸. Valdecoxib is a potent COX-2inhibitor and also contain –SO₂NH₂ group. This group can be condensed with benzoxainone derivatives and the products are novel quinazolinones, which may show better or additional activities. 4-(4-Methyl-3-phenyl-4-isoxazolyl)benzene sulfonamide, empirical formula C₁₆H₁₄N₂O₃S, molecular weight 314.36, is a white crystalline powder, which is relatively insoluble in ethanol, methanol, but freely soluble in

* Author for correspondence; E-mail: meeraharsa@yahoo.com; Sabareesanmuthu@gmail.com

organic solvents and aqueous alkali. Valdecoxib is a nonsteroidal antiinflammatory drug that exhibits antiinflammatory, analgesic and antipyretic properties. The mechanism of action is believed to be due to inhibition of prostaglandin synthesis primarily through inhibition of cyclo-oxygenase-2 (COX-2). At therapeutic plasma concentrations in human, valdecoxib does not inhibit cyclo-oxygenase-1 (COX-1). It was found that when one biodynamic heterocyclic system was coupled with another heterocyclic system, an enhanced biological activity was produced.

EXPERIMENTAL

All the melting points were taken in Veego-Vmp 1 melting point apparatus and are uncorrected. IR spectra were recorded on Perkin-Elmer FT-IR spectrometer. NMR spectra were recorded on Bruker spectrometer 200 MHz and the chemical shifts are referenced to TMS.

Synthesis of compounds²⁹⁻³⁴

Synthesis of 2-phenyl-3, 1-benzoxazin-4-one (PB-1)

To a solution of anthranilic acid (**1a-c**) (0.01 mol) in pyridine (30 mL), benzoylchloride (0.02 mol) was added, and the mixture was shaken for 5 min and then kept aside at room temperature for further 25 min with occasional shaking. The reaction mixture was treated with 5% NaHCO₃ solution (15 mL), filtered, washed with water, dried and the crude product was recrystallised from absolute ethanol.

Synthesis of 2-ethyl-3, 1-benzoxazin-4-one (PB-2)

A mixture of anthranilic acid (0.1 mol) and propionic anhydride (0.2 mol) was refluxed for 4 hr under anhydrous conditions. The excess of propionic anhydride was distilled off under reduced pressure and it was cooled to room temperature. The **PB-2** separated as solid mass. The crude drug thus obtained was recrystallized from absolute alcohol.

Synthesis of 6-bromo-2-methyl-3, 1-benzoxazin-4-one (PB-3)

A mixture of 5-bromoanthranilic acid (0.1 mol) and acetic anhydride (0.2 mol) was refluxed for 4 hr under anhydrous conditions. The excess of acetic anhydride was distilled off under reduced pressure and it was cooled to room temperature. The **PB-3** separated as solid mass. The crude drug thus obtained was recrystallized from absolute alcohol.

Synthesis of 6-bromo-2-phenyl-3, 1-benzoxazin-4-one (PB-4)

To a solution of 5-bromoanthranilic acid (0.01 mol) in pyridine (30 mL), benzoylchloride (0.02 mol) was added, and the mixture was shaken for 5 min and then kept aside at room temperature for further 25 min with occasional shaking. The reaction mixture was treated with 5% NaHCO₃ solution (15 mL), filtered, washed with water, dried and the crude product was recrystallised from absolute ethanol.

Synthesis of 6-bromo-2-ethyl-3, 1-benzoxazin-4-one (PB-5)

A mixture of 5-bromoanthranilic acid (0.1 mol) and propionicanhydride (0.2 mol) was refluxed for 4 hr under anhydrous conditions. The excess of acetic anhydride was distilled off under reduced pressure and cooled to room temperature. The **PB-5** separated as solid mass. The crude drug thus obtained was recrystallized from absolute alcohol.

Synthesis of 6-bromo-2-methyl-3, 1-benzoxazin-4-one (PB-6)

A mixture of 3,5-dibromoanthranilic acid (0.1 mol) and acetic anhydride (0.2 mol) was refluxed for 4 hr under anhydrous conditions. The excess of acetic anhydride was distilled off under reduced pressure and it was cooled to room temperature. The **PB-6** separated as solid mass. The crude drug thus obtained was recrystallized from absolute alcohol.

Synthesis of 6, 8-dibromo-2-phenyl-3, 1-benzoxazin-4-one (PB-7)

To a solution of 5-bromoanthranilic acid (0.01 mol) in pyridine (30 mL), benzoylchloride (0.02 mol) was added and the mixture was shaken for 5 min and then kept aside at room temperature for further 25 min with occasional shaking. The reaction mixture was treated with 5% NaHCO₃ solution (15 mL), filtered, washed with water, dried and the crude product was recrystallised from absolute ethanol.

Synthesis of 6, 8-dibromo-2-ethyl-3, 1-benzoxazin-4-one (PB-8)

A mixture of 3,5-dibromoanthranilic acid (0.1 mol) and propionicanhydride (0.2 mol) was refluxed for 4 hr under anhydrous conditions. The excess of acetic anhydride was distilled off under reduced pressure and it was cooled to room temperature. The **PB-8** separated as solid mass. The crude drug thus obtained was recrystallized from absolute alcohol. The melting points molecular weights, R_f values and yields of the compounds **PB-1** to **PB-8** are given in Table 1.

Synthesis of 2-phenyl-3-{[4-(5-methyl-3-phenyl-4-isoxazolyl)-phenyl]sulfonyl}4-(3H)quinazolinone (PBV-1)

An equimolar (0.1 mol) mixture of 2-phenyl-3,1-benzoxazin-4-one and valdecoxib was refluxed for 6 hr with 10 mL of glacial acetic acid. The mixture was cooled to room temperature and poured into crushed ice. Then it was filtered and dried. The solid thus obtained was recrystallised from absolute alcohol.

Synthesis of 2-ethyl-3-{[4-(5-methyl-3-phenyl-4-isoxazolyl)-phenyl] sulfonyl}4-(3H)quinazolinone (PBV-2)

An equimolar (0.1 mol) mixture of 2-ethyl-3,1-benzoxazin-4-one and valdecoxib was refluxed for 6 hr with 10 mL of glacial acetic acid. The mixture was cooled to room temperature and poured into crushed ice. Then it was filtered and dried. The solid thus obtained was recrystallised from absolute alcohol.

Synthesis of 6-bromo-2-methyl-3-{[4-(5-methyl-3-phenyl-4-isoxazolyl)-phenyl] sulfonyl}4-(3H)quinazolinone (PBV-3)

An equimolar (0.1 mol) mixture of 6-bromo-2-methyl-3,1-benzoxazin-4-one and valdecoxib was refluxed for 6 hr with 10 mL of glacial acetic acid. The mixture was cooled to room temperature and poured into crushed ice. Then it was filtered and dried. The solid thus obtained was recrystallised from absolute alcohol.

Synthesis of 6-bromo-2-phenyl-3-{[4-(5-methyl-3-phenyl-4-isoxazolyl)-phenyl] sulfonyl}4-(3H)quinazolinone (PBV-4)

An equimolar (0.1 mol) mixture of 6-bromo-2-phenyl-3,1-benzoxazin-4-one and Valdecoxib was refluxed for 6 hr with 10 mL of glacial acetic acid. The mixture was cooled to room temperature and poured into crushed ice. Then it was filtered and dried. The solid thus obtained was recrystallised from absolute alcohol.

Synthesis of 6-bromo-2-ethyl-3-{[4-(5-methyl-3-phenyl-4-isoxazolyl)-phenyl] sulfonyl}4-(3H)quinazolinone (PBV-5)

An equimolar (0.1 mol) mixture of 6-bromo-2-ethyl-3,1-benzoxazin-4-one and valdecoxib was refluxed for 6 hr with 10 mL of glacial acetic acid. The mixture was cooled to room temperature and poured into crushed ice. Then it was filtered and dried. The solid thus obtained was recrystallised from absolute alcohol.

Synthesis of 6, 8-dibromo-2-methyl-3-{[4-(5-methyl-3-phenyl-4-isoxazolyl)-phenyl]sulfonyl}-4-(3H) quinazolinone (PBV-6)

An equimolar (0.1 mol) mixture of 6,8-dibromo-2-methyl-3,1-benzoxazin-4-one and valdecoxib was refluxed for 6 hr with 10 mL of glacial acetic acid. The mixture was cooled to room temperature and poured into crushed ice. Then it was filtered and dried. The solid thus obtained was recrystallised from absolute alcohol.

Table 1: Physical data of synthesized compounds

Code	Molecular formula	Molecular weight	Melting point (°C)	% yield	R _f value
PB-1	C ₁₄ H ₉ NO ₂	223.233	120	89	0.75
PB-2	C ₁₀ H ₉ NO ₂	175.188	104	74	0.86
PB-3	C ₉ H ₆ BrO ₂ N	240.57	123	55	0.68
PB-4	C ₁₄ H ₈ BrNO ₂	302.129	180	58	0.87
PB-5	C ₁₀ H ₈ BrNO ₂	254.084	190	69	0.97
PB-6	C ₉ H ₅ Br ₂ NO ₂	318.953	176C	61	0.93
PB-7	C ₁₄ H ₇ Br ₂ NO ₂	381.025	153	60	0.81
PB-8	C ₁₀ H ₇ Br ₂ NO ₂	332.980	158	83	0.85
PBV-1	C ₃₀ H ₂₁ N ₃ O ₄ S	519.574	135	81	0.70
PBV-2	C ₂₆ H ₂₁ N ₃ O ₄ S	471.537	146	77	0.68
PBV-3	C ₂₅ H ₁₈ BrN ₃ O ₄ S	536.397	157	86	0.72
PBV-4	C ₃₀ H ₂₀ BrN ₃ O ₄ S	598.467	155	94	0.69
PBV-5	C ₂₆ H ₂₀ BrN ₃ O ₄ S	550.424	148	97	0.84
PBV-6	C ₂₅ H ₁₇ Br ₂ N ₃ O ₄ S	615.293	168	80	0.58
PBV-7	C ₃₀ H ₁₉ Br ₂ N ₃ O ₄ S	677.363	160	96	0.63
PBV-8	C ₂₆ H ₁₉ Br ₂ N ₃ O ₄ S	629.320	138	78	0.71

Synthesis of 6, 8-dibromo-2-phenyl-3-{[4-(5-methyl-3-phenyl-4-isoxazolyl)-phenyl] sulfonyl} 4-(3H) quinazolinone (PBV-7)

An equimolar (0.1 mol) mixture of 6,8-dibromo-2-phenyl-3,1-benzoxazin-4-one and valdecoxib was refluxed for 6 hr with 10 mL of glacial acetic acid. The mixture was cooled to room temperature and poured into crushed ice. Then it was filtered and dried. The solid thus obtained was recrystallised from absolute alcohol.

Synthesis of 6, 8-dibromo-2-ethyl-3-{[4-(5-methyl-3-phenyl-4-isoxazolyl)-phenyl] dulfonyl}-4-(3H) quinazolinone (PBV-8)

An equimolar (0.1 mol) mixture of 6,8-dibromo-2-ethyl-3,1-benzoxazin-4-one and valdecoxib was refluxed for 6 hr with 10 mL of glacial acetic acid. The mixture was cooled to room temperature and poured into crushed ice. Then it was filtered and dried. The solid thus obtained was recrystallised from absolute alcohol. The melting points, molecular weight, R_f values and yields of the compounds **PBV-1** to **PBV-8** are given in Table 1.

Spectral analysis of the compounds³³⁻³⁵

PB-1: IR (KBr): 1764 (C=O str), 1612 (C = Nstr) cm^{-1}

PMR (200MHz; CDCl_3): δ 7.63-8.34 (m, 9H, Ar-H)

PB-2: IR (KBr): 1685 (C=O str), 1640 (C = N str) cm^{-1}

PB-3: IR (KBr): 1700 (C=O str), 1613 (C=N str), 530 (C-Br str) cm^{-1}

PB-4: IR (KBr): 1755(C=O str), 1578(C=N str), 560(C-Br str) cm^{-1}

PB-5: IR (KBr): 1700(C=O str), 1613(C=N str), 530(C-Br str) cm^{-1}

PB-6: IR (KBr): 1712(C=O str), 1598(C=N str), 532 (C-Br str) cm^{-1}

PB-7: IR (KBr): 1756(C=O str), 1614(C=N str), 583,537 (C-Br str) cm^{-1}

PB-8: IR (KBr): 1774(C=O str), 1579(C=N str), 530,554 (C-Br str) cm^{-1}

PBV-1: IR (KBr): 1643(C=O str), 1333 and 1150(S=O str), 1599 (C=N str) cm^{-1}

PMR (200MHz; DMSO): δ 1.54 (s, 3H, CH_3) 7.63-8.34 (m, 18H, Ar-H)

PBV-2: IR (KBr): 1678 (C=O str), 1332 and 1150(S=O str), 1465 (C=N str) cm^{-1}

PMR (200MHz; DMSO): δ 0.69 (t, 3H, CH_3 . CH_2) 1.39 (q, 2H, CH_2CH_3), 1.85 (s, 3H, CH_3), 6.80-6.95 (m, 13H, Ar-H)

PBV-3: IR (KBr): 1663 (C=O str), 1333 and 1150 (S=O str), 1578 (C=N str) cm^{-1}

PMR (200MHz; CDCl_3): δ 1.22 (s, 3H, CH_3) 1.56 (s, 3H, CH_3), 6.52-7.51 (m, 11H, Ar-H)

PBV-4: IR (KBr): 1664(C=O str), 1338 and 1156 (S=O str), 1597(C=N str) cm^{-1}

PMR (200MHz; DMSO): δ 1.56 (s, 3H, CH_3)6.47-7.77(m, 17H, Ar-H)

PBV-5: IR (KBr): 1656(C=O str), 1334 and 1150(S=O str), 1502 (C=N str) cm^{-1}

PMR (200MHz; DMSO): δ 0.68 (t, 3H, CH_3 . CH_2)1.41 (q, 2H, CH_2 . CH_3), 1.82 (s, 3H, CH_3), 6.62-6.92 (m, 12H, Ar-H)

PBV-6: IR (KBr): 1663(C=O str), 1333 and 1151(S=O str), 1598 (C=N str) cm^{-1}

PMR (200MHz; DMSO): δ 1.20 (s, 3H, CH_3)1.55 (s, 3H, CH_3), 6.46-7.51 (m, 11H, Ar-H)

PBV-7: IR (KBr): 1662(C=O str), 1332 and 1156(S=O str), 1578 (C=N str) cm^{-1}

PMR (200MHz; CDCl_3): δ 1.54 (s, 3H, CH_3), 7.63-8.34(m, 18H, Ar-H)


PBV-8: IR (KBr): 1656(C=O str), 1334 and 1150 (S=O str), 1502 (C=N str) cm^{-1}

PMR (200MHz; DMSO): δ 0.68 (t, 3H, CH_3 . CH_2) 1.41 (q, 2H, CH_2 . CH_3), 1.82 (s, 3H, CH_3), 6.62-6.92 (m, 12H, Ar-H).

RESULTS AND DISCUSSION

Eight novel quinazolinone derivatives were synthesized and characterized by spectral analysis. 2-Phenyl/ethyl,6-bromo-2-methyl/6-bromo-2-phenyl/6-bromo-2-ethyl and 6,8-dibromo-2-methyl/6,8-dibromo-2-phenyl/6,8-dibromo-2-ethyl3-{[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl}-4-(3H)quinoxolinone were synthesized by refluxing equimolar amounts of 2-substituted-3,1-benzoxazin-4-one and valdecoxib in the presence of glacial acetic acid. The melting point of the synthesized compounds was found out by open capillary tube method and the results are uncorrected. The purity of the compounds was checked by TLC using silica gel G as an adsorbent, ethyl acetate and chloroform (9.8 : 0.2) were used as mobile phase. The spot was visualized by iodine vapor or dinitrophenylhydrazine solution. The structure of the synthesized compounds was characterized by its IR and ^1H NMR spectral analysis, where it complies with the normal values.

Scheme 1



X = C_6H_5COCl

2 & 5 R = C_6H_5

Y = $(CH_3CH_2CO)_2 O/heat/4 hr$

3 & 6 R = C_2H_5

Z = $(CH_3CO)_2 O/heat/4 hr$

4 & 7 R = CH_3

REFERENCES

1. B. R. Baker, Robert. E. Schaub, Joseph P. Joseph, Francis. J. McEvoy and James H. Williams, An Antimalarial Alkaloid from Hydrangea, *J. Org. Chem.*, **17**, 149-156. (1952).

2. Elliott Cohen, Betty Klarberg and James R. Vaughan., Quinazolinone Sulfonamides. A New Class of Diuretic Agents, *J. Am. Chem. Soc.*, **82**, 2731-2735 (1960).
3. Shin Hayao, Herbert J. Havera, Wallace G. Strycker, T. J. Leipzig, Richard A. Kulp and Harold E. Hartzler, New Sedative and Hypotensive-3-Substituted 2, 4-(1H, 3H) Quinazolinones, *J. Med. Chem.*, **8**, 807-811 (1965).
4. Surendra S. Parmar and R. C. Arora, Synthesis of Quinazolone Hydrazides as Monoamine Oxidase Inhibitors, *Can. J. Chem.*, **44**, 2100-2102 (1966).
5. Surendra S. Parmar and R. C. Arora, Some 2, 3, 6, 8-Tetra Substituted Quinazolone Hydrazides as Monoamine Oxidase Inhibitors, *J. Med. Chem.*, **10(6)**, 1182-1183 (1967).
6. Surendra S. Parmar and R. C. Arora. Synthesis of Substituted Quinazolone Hydrazides, *Can. J. Chem.*, **46**, 2519-2524 (1968).
7. H. J. Hess, T. H. Cronin and A. Scriabine, Antihypertensive 2-Amino-4-(3H)-Quinazolinones, *J. Med. Chem.*, **11**, 130-136 (1968).
8. Surendra S. Parmar and R. Kumar, Substituted Quinazolone Hydrazides as Possible Antituberculous Agents., *J. Med. Chem.*, **11(3)**, 635-636 (1969).
9. S. Somaskehara, V. S. Dighe, S. H. Parikh and S. V. Gokhale. 3-Aryl-2-isopropyl and 2-Aryl 3-isopropyl Derivatives of 4-(3H)-Quinazolones, *Indian J. Pharm.*, **33(1)** 96-97 (1971).
10. Okumura Oine, Yamada, Hayashi and Nakama, Synthesis and Pharmacological Properties of 2-Methyl-3-aryl-4-oxo-1, 2, 3, 4-tetra hydroquinazolines and their 1-Acyl Derivatives, *J. Med. Chem.*, **11**, 348-352 (1969).
11. Bonola, Da re, Magistretti, Massarani and Setnikar, 1-Aminoacyl-2, 3-dihydro-4-(1H) Quinazolionone Derivatives with Choleric and Antifibrillatory Activity, *J. Med. Chem.*, **11**, 1136-1139 (1968).
12. Shin Hayao, H. J. Havera and W. G. Strycker, Hypertensive, Antiadrenergic and Antihistaminic 3-Substituted 2-Methyl or 2-Phenyl 4-3H) Quinazolones, *J. Med. Chem.*, **12**, 936-938 (1970).
13. R. Kumar, T. K. Gupta and Surendra S. Parmar, CNS Depressant Activity of Quinazolones Azomethines, *Indian J. Pharm.*, **33(6)**, 108-110 (1971).
14. D. D. Mukerji, S. R. Nautiyal and C. R. Prasad, Synthesis of Some New N'-[4-(3H)-Quinazolone-3-yl]-methylmorpholine, Malonyl Urea and Piperazines as CNS Depression compounds, *Indian J. Pharm. Sc.*, **40(2)**, 44-47 (1978).

15. S. Nagar and Surendra S. Parmar, Pharmacological Properties of Substituted 2-methyl-3-(2', 4'-dimethylphenyl)-4-quinazolones, *Indian J. Pharm.*, **33(4)**, 61-64 (1971).
16. V. K. Rastogi, S. S. Parmar, S. P. Singh and T. K. Akers, Synthesis of 2-Methyl-3-(3, 5-diaryl-4-hydroxyphenyl)-4-quinazolones as Possible Anticonvulsants, *J. Heterocyclic Chem.*, **15**, 497-499 (1978).
17. Surendra S. Parmar and Shiva P. Singh, Synthesis of Substituted 2-Methyl-3-(3, 4-dimethoxy/dihydroxyphenylethyl)-4-quinazolones as Possible Antiparkinsonism Drugs, *J. Heterocyclic Chem.*, **16**, 449-452 (1979).
18. K. Shankar, Vijai K. Srivastava, I. P. Singh, Sharadha Singh and M. B. Gupta, Synthesis of Some Quinazolones, *Indian J. Pharm. Sci.*, **48(5)**, 133-136 (1986).
19. A. K. Sengupta, M. M. Gupta and Anurag Ateet Gupta, Synthesis of 6, 8-Disubstituted 3-(4-[N-(N'-arylcarbonyl) Carbamoylmethoxy]-2-phenylquinazolin-4-(3H)-ones as Possible Antibacterial Agents, *Indian J. Chem.*, **21**, 600-602 (1982).
20. C. H. Ravi Shankar, A. Devandar Rao, E. Jahasena Reddy and V. Malla Reddy. Synthesis and Biological Activities of Certain Derivatives of 3-Aryl-4-(3H)-Quinazolinones, *J. Indian Chem. Soc.*, **60**, 61-63 (1983).
21. Anil K. Sengupta, Tapas Bharracharya, Ashok K. Pandey, H. N. Verma and M. M. Abid Alikhan, Antiviral Evaluation of 2-Substituted-3-arylquinazolin-4(3H)-ones, *Indian Drugs.*, 435-437 (1984).
22. Nortan P. Peet, Larry E. Baugh, Shyam Sunder, John E. Lewis, Emily H. Mathews, Edward L. Oleberding and Dhiren N. Shah, 3-(1H-Tetrazol-5-yl)-4-(3H)-quinazolinone Sodium Salt, A New Antiallergic Agent, *J. Med. Chem.*, **29**, 2403-2409 (1986).
23. V. K. Pandey and Punita Garg, Synthesis of Quinazolinyl Triazines as Potential Anthelmintics, *Indian J. Pharm. Sci.*, **49(5)**, 172-174 (1987).
24. J. B. Jiang, D. P. Hesson, B. A. Dusak, D. L. Dexter, G. J. Kang and E. Hamel. Synthesis and Biological Evaluation of 2-Stryl Quinazolinones, a New Class of Antimitotic, Anticancer Agents, which Inhibit Tubulin Polymerization, *J. Med. Chem.*, **33**, 1721-1728 (1990).
25. N. C. Desai, B. R. Shah, J. J. Bhatt, H. H. Patel, N. K. Undavia and P. B. Trivedi. Synthesis of 2, 3-Disubstituted-3, 1-quinazolin-4-(4H)-one as Potential Anticancer and Anti-HIV Agents, *Indian J. Chem.*, **34**, 201-208 (1995).

26. Ashok Kumar, Ritu Tyagi, Ekta Bansal, R. S. Verma, K. K. Saxena and V. K. Srivastava, 2-Methyl-3-[5-(substituted phenyl)- Δ^2 -triazoline-4-(3H)-quinazolinones as Potential Cardiovascular Drugs, *Indian Drugs.*, **35(5)**, 261-265 (1998).
27. K. L. Dhar, S. C. Sharma and V. Zutshi, Structure Elucidation of Two More Metabolites of 7, 8, 9, 10-Tetrahydroazepino [2, 1] quinazolin-12-(6H)-one, Apotent Bronchodilator, *Indian J. Chem.*, **38**, 814-817 (1999).
28. D. I. Bain and R. K. Smalley, Synthesis of 2-Substituted 4H-benzoxainone, *J. Chem. Soc.*, 1593-1597 (1969).
29. M. B. Deshmukh and D. S. Deshmukh, Synthesis and Biological Activity of Some New Quinazolinyl Thiazolidones and Azetidiones, *J. Indian Chem. Soc.*, **72**, 847-848, (1995).
30. Surendra S. Parmar and R. Kumar, Substituted Quinazolone Hydrazides as as Possible Antituberculous Agents., *J. Med. Chem.*, **11(3)**, 635-636 (1969).
31. Pradeep Mishra, P. N. Gupta and Ashok K. Shakya, Synthesis of Some Schiff Bases of 3-Amino-2-methyl quinazoline 4-(3H)-one and their Antimicorobial Activities, *J. Indian Chem. Soc.*, **68**, 618-619 (1991).
32. P. Selvam, K. Vanitha, M. Chandramohan and E. De. Clercq, Synthesis and Anti-microbial Activity of Some Novel 6-Bromo-2-methyl/phenyl3-(sulphonamido) quinazolin-4-(3H) one, *Indian J. Pharm. Sci.*, **66(6)**, 82-86 (2004).
33. John R. Dyer, Applications of Absorption Spectroscopy of Organic Compounds, 1st Edition, Prentice-Hall of India (P), New Delhi, (1969) pp. 33-38.
34. Robert M. Silverstein and Francis X. Webster, Spectrometric Identification of Organic Compounds, John Wiley and Sons, Inc. (1998).
35. F. W. McLafferty, Interpretation of Mass Spectra, 2nd Edition, W. A. Benjamin. Inc. Publishers, NewYork (1974).

Accepted : 07.10.2009